NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

The objective third party that vets the MOA will be the regulator. No doubt the proteomic analysis are included in regulatory applications.

Why else would they pay a firm to do this work now, when they don't have a lot of cash, unless it was necessary for approval which we know are their primary goal not publishing another journal?

Yet instead of thinking about context all you can do are raising moot points about a peer reviewed journal.

Some like attention.

Others get work done.